Skip to main content
SpringerLink
Log in

The human tumor clonogenic assay used to study ovarian cancers

  • Chapter
Ovarian Cancer

Part of the book series: Cancer Treatment and Research ((CTAR,volume 23))

Abstract

During the last decade, the treatment of ovarian cancer has changed markedly as the available armamentarium of cytotoxic drugs has improved. It remains apparent that surgical cytoreduction (debulking) procedures are useful, particularly in those cases where the largest mass of residual tumor can be reduced to less than 1 cm in size [1]. However, even more important than the degree of surgical debulking which can be achieved is the apparent improvement in clinical response rates seen with new innovations in chemotherapy. The Gynecologic Oncology Group (GOG) conducted a large randomized trial between 1976 and 1979 of suboptimal (> 3 cm tumor bulk) untreated ovarian cancers (Protocol #22), which showed that melphalan alone was as effective as the combination of cyclophosphamide and doxorubicin in the observed response rates and survival durations [2]. However, the subsequent GOG Protocol # 47 showed that the addition of cisplatin to cyclophosphamide and doxorubicin improved response rates from 46% to 71% with the median duration of survival increasing from 9.5 months to 15.0 months [3]. The fact, however, becomes apparent that a. survival duration of 15 months is not a cure, and the good benefits which cisplatin bestowed on patients with ovarian cancers are limited. The empiric choice of chemotherapeutic agents does not necessarily provide maximal benefit to each patient with ovarian cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Griffiths CT: Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. National Cancer Institute Monograph 42:101–104, 1975.

    PubMed  CAS  Google Scholar 

  2. Omura GA, Blessing JA, Morrow CP, Buchsbaum HJ, Homesley HD: Follow-up on a randomized trial of melphalan vs. melphalan plus hexamethylmelamine vs. adriamycin plus cyclophosphamide in advanced ovarian adenocarcinoma. Proc Am Soc Clin Oncol 22:470, 1981.

    Google Scholar 

  3. Omura GA, Ehrlich CE, Blessing JA: A randomized trial of cyclophosphamide plus adriamycin with or without cisplatinum in ovarian carcinoma. Proc Am Soc Clin Oncol 1:104, 1982.

    Google Scholar 

  4. Hamburger AW, Salmon SE: Primary bioassay of human tumor stem cells. Science 197:461–463, 1977.

    Article  PubMed  CAS  Google Scholar 

  5. Salmon SE, Hamburger AW, Soehnlen B, Durie BGM, Alberts DS, Moon TE: Quantitation of differential sensitivity of human tumor stem cells to anticancer drugs. N Engl J Med 298:1321–1327, 1978.

    Article  PubMed  CAS  Google Scholar 

  6. Hamburger AW, Salmon SE, Kim MB, et al.: Direct cloning of human ovarian carcinoma cells in agar. Cancer Res 38:3438–3444, 1978.

    PubMed  CAS  Google Scholar 

  7. Fogh J, Trempe G: New Human tumor cell lines. In: Human tumor cells in vitro, Fogh J (ed), New York, Plenum Press, 1975, pp 115–159.

    Google Scholar 

  8. DiSaia PJ, Morrow M, Kanabus J, Piechal W, Townsend DE: Two new tissue culture lines from ovarian cancer. Gynecol Oncol 3:215–219, 1975.

    Article  PubMed  CAS  Google Scholar 

  9. Sinna GA, Beckman G, Lundgren E, Nordenson I, Roos G: Characterization of two new human ovarian carcinoma cell lines. Gynecol Oncol 7:267–280, 1979.

    Article  PubMed  CAS  Google Scholar 

  10. Kimoto T, Ueki A, Nishitani K: A human malignant cell line established from ascites of patient with embryonal carcinoma of ovarium. Acta Pathol Jpn 25:89–98, 1975.

    PubMed  CAS  Google Scholar 

  11. Freedman RS, Pihl E, Kusyk C, Gallager HS, Rutledge F: Characterization of an ovarian carcinoma cell line. Cancer 42:2352–2359, 1978.

    Article  PubMed  CAS  Google Scholar 

  12. Yamada T: The cellular biology of a newly established cell line of human ovarian adenocarcinoma in vitro. Keio J Med 23:53–70, 1974.

    Article  PubMed  CAS  Google Scholar 

  13. Woods LK, Morgan RT, Quinn LA, Moore GE: Comparison of four new cell lines from patients with adenocarcinoma of the ovary. Cancer Res 39:4449–4459, 1979.

    PubMed  CAS  Google Scholar 

  14. Soehnlen B, Young L, Liu R: Standard laboratory procedures for in vitro assay of human tumor stem cells. In: Cloning of human tumor stem cells, Salmon SE (ed), New York, Alan R. Liss, Inc., 1980, pp 331–338.

    Google Scholar 

  15. Pavelic ZP, Slocum HK, Rostum YM, Creaven PJ, Karakousis C, Takita H: Colony growth in soft agar of human melanoma, sarcoma, and lung carcinoma cells disaggregated by mechanical and enzymatic methods. Cancer Res 40:2160–2164, 1980.

    PubMed  CAS  Google Scholar 

  16. Salmon SE, Buick RN: Preparation of permanent slides of intact soft-agar colony cultures of hematopoietic and tumor stem cells. Cancer Res 39:1133–1136, 1979.

    PubMed  CAS  Google Scholar 

  17. Moon TE: Quantitative and statistical analysis of the association between in vitro and in vivo studies. In: Cloning of human tumor stem cells, Salmon SE (ed), New York, Alan R. Liss, Inc., 1980, pp 209–221.

    Google Scholar 

  18. Williams TJ, Lieber MM, Podratz KC, Malkasian GD Jr: Soft agar colony formation assay for in vitro testing of sensitivity to chemotherapy of gynecologic malignancies. Am J Obstet Gynecol 145:940–947, 1983.

    Google Scholar 

  19. Sikic BI, Evans TL, MacKintosh FR, Smith HS: Human tumor clonogenic assays — studies of growth and drug sensitivity. Proc Amer Assoc Cancer Res 23:186, 1982.

    Google Scholar 

  20. Natale RB, Kushner B: Applications of the human tumor cloning assay to ovarian cancer. Proc Amer Assoc Cancer Res 22:156, 1981.

    Google Scholar 

  21. Von Hoff DD, Cowan J, Harris G, Reisdorf G: Human tumor cloning: feasibility and clinical correlations. Cancer Chemother Pharmacol 6:265–271, 1981.

    Google Scholar 

  22. Ozols RF, Willson JKV, Grotzinger KR, Young RC: Cloning of human ovarian cancer cells in soft agar from malignant effusions and peritoneal washings. Cancer Res 40:2743–2747, 1980.

    PubMed  CAS  Google Scholar 

  23. Welander CE, Homesley HD, Jobson VW: In vitro chemotherapy testing of gynecologic tumors: Basic for planning therapy? Am J Obstet Gynecol 147:188–195, 1983.

    PubMed  CAS  Google Scholar 

  24. Buick RN, Fry SE, Salmon SE: Effect of host cell interactions on clonogenic carcinoma cells in human malignant effusions. Br J Cancer 41:695–704, 1980.

    Article  PubMed  CAS  Google Scholar 

  25. Welander CE, Natale RB, Lewis JL Jr: In vitro growth stimulation of human ovarian cancer cells by xenogeneic peritoneal macrophages. J Natl Cancer Inst 69:1039–1047, 1982.

    PubMed  CAS  Google Scholar 

  26. Gaines JT, Welander CE, Homesley HD: Improved cloning efficiency in the human tumor stem cell assay using Ficoll gradient separation. Proc Amer Assoc Cancer Res 24:311, 1983.

    Google Scholar 

  27. Alberts DS, Chen HSG, Soehnlen B, Salmon S, Surwit EA, Young L: In vitro clonogenic assay for predicting response of ovarian cancer to chemotherapy. Lancet (Aug 16) 340–342, 1980.

    Article  Google Scholar 

  28. Alberts DS, Chen HSG, Young L, et al.: Improved survival for relapsing ovarian cancer patients using the human tumor stem cell assay to select chemotherapy. Proc Amer Soc Clin Oncol 22:462, 1981.

    Google Scholar 

  29. Coldman AJ, Goldie JH: A mathematical model of drug resistance in neoplasms. In: Drug and hormone resistance in neoplasia, Vol. 1, Bruchovsky N, Goldie JH (eds), Boca Raton, Florida, CRC Press, Inc., 1982, pp 55–78.

    Google Scholar 

  30. Alberts DS, Salmon SE, Surwit EA, Chen HSG, Moon TE, Meyskens FL: Combination chemotherapy in vitro with the human tumor stem cell assay. Proc Amer assoc Cancer Res 22:153, 1981.

    Google Scholar 

  31. Sondak VK, Korn El, Morton DL, Kern DH: Absence od in vitro synergy for chemotherapeutic combinations tested in the clonogenic assay. Proc Amer Assoc Cancer Res 24:316, 1983.

    Google Scholar 

  32. Day TG, Gallager HS, Rutledge FN: Epithelial carcinoma of the ovary: prognostic importance of histologic grade. National Cancer Institute monograph 42:15–18, 1975.

    PubMed  Google Scholar 

  33. Ozols RF, Garvin AJ, Costa J, Simon RM, Young RC: Histologic grade in advanced ovarian cancer. Cancer Treatment Reports 63:255–263, 1979.

    PubMed  CAS  Google Scholar 

  34. Stanley KE: Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst 65:25–32, 1980.

    PubMed  CAS  Google Scholar 

  35. Volm M: In vitro short-term test to determine the resistance of human tumors to chemotherapy. Cancer 48:2127–2135, 1981.

    Article  Google Scholar 

  36. Epstein LB, Shen JT, Abele JS, Reese CC: Sensitivity of human ovarian carcinoma cells to interferon and other antitumor agents as assessed by an in vitro semisolid agar technique. Ann NY Acad Sci 350:228–244, 1980.

    Article  PubMed  CAS  Google Scholar 

  37. Salmon SE, Durie BGM, Young L, Liu RM, Trown PW, Stebbing N: Effects of cloned human leukocyte interferons in the human tumor stem cell assay. J Clin Oncol 1:217–225, 1983.

    PubMed  CAS  Google Scholar 

  38. Aapro MS, Alberts DS, Salmon SE: Interaction of human leukocyte interferon with vinca alkaloids and other chemotherapeutic agents against human tumors in clonogenic assay. Cancer Chemother Pharmacol, 10:161–166, 1983.

    Article  PubMed  CAS  Google Scholar 

  39. Welander C, Gaines J, Homesley H, Rudnick S: In vitro synergistic effects of recombinant human interferon alpha2 and doxorubicin on human tumor cell lines. Proc Amer Soc Clin Oncol 2:42, 1983.

    Google Scholar 

  40. Dedrick RL, Myers CE, Bungay PM, DeVita VT Jr: Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treatment Reports 62:1–11, 1978.

    PubMed  CAS  Google Scholar 

  41. Jones RB, Myers CE, Guarino AM, Dedrick RL, Hubbard SM, DeVita VT: High volume intraperitoneal chemotherapy (2 belly bath’) for ovarian cancer. Cancer Chemother Pharmacol 1:161–166, 1978.

    Article  PubMed  CAS  Google Scholar 

  42. Howell SB, Pfeifle CL, Wung WE, et al.: Intraperitoneal cisplatin with systemic thiosulfate protecion. Ann Int Med 97:845–851, 1982.

    PubMed  CAS  Google Scholar 

  43. Salmon S, Alberts D, Meyskens F: A new concept. In Vitro phase II trial with the human tumor stem cell assay. Proc Am Soc Clin Oncol 21:329, 1980.

    Google Scholar 

  44. Slayton R, Petty W, Blessing J: Phase II trial of VP-16 in treatment of advanced ovarian adenocarcinoma. Proc Amer Assoc Cancer Res 20:190, 1979.

    Google Scholar 

  45. Shoemaker Rh, Wolpert-Defilippes MK, Makuch RW, Venditti JM: Use of the human tumor clonogenic assay for new drug screening. Proc Amer assoc Cancer Res 24:311, 1983.

    Google Scholar 

Download references

Authors
  1. Charles E. Welander
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Internal Medicine Section of Hematology & Oncology, University of Arizona Health Sciences Center, Tucson, Arizona, USA

    David S. Alberts

  2. Department of Obstetrics & Gynecology, University of Arizona Health Sciences Center, Tucson, Arizona, USA

    Earl A. Surwit

Rights and permissions

Reprints and permissions

Copyright information

© 1985 Martinus Nijhoff Publishers, Boston

About this chapter

Cite this chapter

Welander, C.E. (1985). The human tumor clonogenic assay used to study ovarian cancers. In: Alberts, D.S., Surwit, E.A. (eds) Ovarian Cancer. Cancer Treatment and Research, vol 23. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-2561-1_3

Download citation

  • DOI: https://doi.org/10.1007/978-1-4613-2561-1_3

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4612-9609-6

  • Online ISBN: 978-1-4613-2561-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation